Compare · BLLN vs ILMN
BLLN vs ILMN
Side-by-side comparison of BillionToOne Inc. (BLLN) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLLN and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $19.43B, about 5.0x BLLN ($3.90B).
- Over the past year, BLLN is down 22.5% and ILMN is up 65.7% - ILMN leads by 88.2 points.
- ILMN has been more active in the news (5 items in the past 4 weeks vs 3 for BLLN).
- ILMN has more recent analyst coverage (25 ratings vs 8 for BLLN).
- Company
- BillionToOne Inc.
- Illumina Inc.
- Price
- $85.07+1.25%
- $127.93+2.01%
- Market cap
- $3.90B
- $19.43B
- 1M return
- +10.49%
- +1.37%
- 1Y return
- -22.47%
- +65.69%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2000
- News (4w)
- 3
- 5
- Recent ratings
- 8
- 25
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest BLLN
- SEC Form DEFA14A filed by BillionToOne Inc.
- SEC Form DEF 14A filed by BillionToOne Inc.
- BillionToOne to Report First Quarter 2026 Financial Results on May 6, 2026
- BillionToOne Appoints Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development, Oncology
- SEC Form 10-K filed by BillionToOne Inc.
- BillionToOne Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits
- BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance
- SEC Form SCHEDULE 13G filed by BillionToOne Inc.
- BillionToOne to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
- SEC Form SCHEDULE 13G filed by BillionToOne Inc.
Latest ILMN
- DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows
- Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease
- Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026
- SEC Form DEFA14A filed by Illumina Inc.
- SEC Form DEF 14A filed by Illumina Inc.
- SEC Form 4 filed by Ullem Scott B.
- SEC Form 4 filed by Meister Keith A.
- Illumina Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Illumina Announces Changes to Board of Directors
- Amendment: SEC Form SCHEDULE 13G/A filed by Illumina Inc.